Treace Medical CEO buys 55,944 shares in August
TREACE MEDICAL CONCEPTS, INC.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
TREACE MEDICAL CONCEPTS, INC. (TMCI) CEO and director John T. Treace reported open‑market purchases of a total of 55,944 shares of common stock on August 20, 21 and 24, 2026 at weighted average prices of $4.44, $4.35 and $4.34 per share, respectively. The filing also reports several large indirect common stock holdings held by his spouse and in various trusts, for which he disclaims beneficial ownership, and notes that his reported holdings include 542,784 restricted stock units. The Rule 10b5‑1 checkbox is not marked, indicating these purchases were not reported as made under a trading plan.
Insights
Analyzing...
Insider Trade Summary
Net Buyer: 55,944 shares
Net Buy
7 txns
Insider
Treace John T.
Role
Chief Executive Officer
Bought
55,944 shs ($247K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Common Stock F3, F2 | 11,000 | $4.3392 | $48K |
| Purchase | Common Stock F2 | 5,000 | $4.3495 | $22K |
| Purchase | Common Stock F1, F2 | 39,944 | $4.4356 | $177K |
| holding | Common Stock F4 | -- | -- | -- |
| holding | Common Stock F4 | -- | -- | -- |
| holding | Common Stock F5 | -- | -- | -- |
| holding | Common Stock F5 | -- | -- | -- |
Holdings After Transaction:
Common Stock — 7,404,383 shares (Direct);
Common Stock — 1,605,000 shares (Indirect, By spouse);
Common Stock — 1,471,250 shares (Indirect, By spouse as trustee of a trust);
Common Stock — 1,839,063 shares (Indirect, As trustee of a trust);
Common Stock — 408,816 shares (Indirect, As co-trustee of a trust)
Footnotes (5)
- F1. The price reported in Column 4 is a weighted average purchase price. These shares were bought in multiple transactions at prices ranging from $4.3198 to $4.5048 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote.
- F2. Includes 542,784 restricted stock units.
- F3. The price reported in Column 4 is a weighted average purchase price. These shares were bought in multiple transactions at prices ranging from $4.3097 to $4.3489 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote.
- F4. The Reporting Person disclaims beneficial ownership of shares held by his wife directly or in trusts for which his wife serves as trustee or co-trustee.
- F5. The Reporting Person disclaims beneficial ownership of shares held in trust for which he serves as trustee or co-trustee.
Key Figures
Total shares purchased: 55,944 shares
Purchase price August 20, 2026: $4.4356 per share
Purchase price August 21, 2026: $4.3495 per share
+5 more
8 metrics
Total shares purchased
55,944 shares
Common stock bought by John T. Treace on August 20–24, 2026
Purchase price August 20, 2026
$4.4356 per share
Weighted average purchase price; trades from $4.3198 to $4.5048
Purchase price August 21, 2026
$4.3495 per share
Weighted average purchase price for 5,000 shares
Purchase price August 24, 2026
$4.3392 per share
Weighted average purchase price; trades from $4.3097 to $4.3489
Restricted stock units included
542,784 restricted stock units
Included in reported share holdings
Indirect holding by spouse
1,605,000 shares
Common stock held by spouse; beneficial ownership disclaimed
Indirect holding in spouse trust
1,471,250 shares
Common stock held by spouse as trustee of a trust; disclaimed
Indirect holdings in trusts
1,839,063 and 408,816 shares
Common stock held in trusts where he is trustee or co‑trustee; disclaimed
Key Terms
weighted average purchase price, restricted stock units, beneficial ownership, Rule 10b5-1
4 terms
weighted average purchase price financial
"The price reported in Column 4 is a weighted average purchase price."
The weighted average purchase price is the average cost per share you paid across multiple buys, calculated so larger purchases count more than smaller ones. Imagine buying apples at different prices: the overall price you effectively paid depends on how many apples you bought at each price. Investors use it to measure true cost basis, calculate gains or losses, decide when to sell, and manage taxes and portfolio performance.
restricted stock units financial
"Includes 542,784 restricted stock units."
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
beneficial ownership financial
"The Reporting Person disclaims beneficial ownership of shares held by his wife"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
Rule 10b5-1 regulatory
"The Rule 10b5-1 checkbox is not marked, indicating no trading plan"
Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did TMCI CEO John T. Treace report in this Form 4?
He reported open‑market purchases of a total of 55,944 shares of TREACE MEDICAL CONCEPTS, INC. common stock on August 20, 21 and 24, 2026 at weighted average prices around $4.34–$4.44 per share, plus updated indirect holdings and restricted stock units.
Over what price ranges were the August 2026 TMCI purchases executed?
The August 20, 2026 purchases were executed between $4.3198 and $4.5048 per share. The August 24, 2026 purchases were executed between $4.3097 and $4.3489 per share. The reported prices are weighted averages for multiple trades within each range.
What indirect TMCI holdings associated with John T. Treace are disclosed?
Indirect holdings include 1,605,000 shares held by his spouse, 1,471,250 shares held by his spouse as trustee of a trust, 1,839,063 shares held in a trust for which he is trustee, and 408,816 shares held in a trust for which he is co‑trustee.
How many restricted stock units are included in John T. Treace’s TMCI holdings?
The reported holdings include 542,784 restricted stock units of TREACE MEDICAL CONCEPTS, INC., as noted in a footnote clarifying that these RSUs are part of the reported share total.
AI-generated analysis. How Rhea-AI works. Not financial advice.
